🇬🇧 MHRA UK NAMs Pathway

← Back to Agencies

Overview

The Medicines and Healthcare products Regulatory Agency (MHRA) is the independent regulator responsible for authorizing and monitoring medicines, medical devices, and blood components for transfusion in the UK. Post-Brexit, the MHRA has established independent regulatory pathways while maintaining strategic alignment with international partners. The MHRA is actively exploring acceptance of New Approach Methodologies (NAMs) in regulatory submissions, positioning the UK as an innovation-friendly jurisdiction for alternative methods development.

MHRA's Post-Brexit NAMs Strategy

The MHRA is pursuing a position of "alignment with flexibility" - accepting globally validated methods while maintaining independent assessment authority. The agency works closely with EMA and FDA, but now has freedom to set more rapid NAMs acceptance policies. This has resulted in faster integration of novel methods including organoids, organ-on-chip systems, and computational toxicology into routine regulatory assessments.

Acceptable NAMs Technologies

• Organ-on-Chip Systems: Hepatotoxicity, nephrotoxicity, and cardiac safety assessment
• 3D Organoid Models: Disease modeling, genetic disorder research, and drug response prediction
• Reconstructed Human Tissue Models: Skin irritation, eye irritation, and intestinal permeability
• iPSC-Derived Cellular Systems: Patient-derived models, genetic disease studies, and personalized medicine
• Computational Toxicology: QSAR models, machine learning predictions, and AI-based safety assessment
• High-Throughput Screening: Automated phenotypic assessment and target identification
• Pharmacokinetic Prediction Models: In silico ADME prediction and bioavailability assessment

Regulatory Pathway for NAMs in UK

Step 1: Pre-Submission Assessment Meeting

Contact MHRA's Advanced Therapies Division or relevant therapeutic area team for pre-submission advice (PSA). Submit 30-40 page package including NAMs methodology, preliminary data (20-50 compounds), and proposed validation strategy. MHRA provides written feedback within 30 days on acceptability and identifies data requirements.

Step 2: Clinical Trial Application (CTA) Submission

Include NAMs methodology and supporting validation data in nonclinical assessment section of CTA. Format according to MHRA guidance, providing detailed method description, quality control documentation, and mechanism of action studies. Reference any FDA ISTAND or EMA SAWP approvals if applicable.

Step 3: CTA Assessment

MHRA conducts risk-based assessment of NAMs methodology as part of overall nonclinical evaluation. Typical CTA review period is 30 days. MHRA may request additional comparative studies or mechanistic data if method novelty raises questions about human relevance.

Step 4: Marketing Authorization Application (MAA)

Include comprehensive nonclinical assessment integrating NAMs results alongside traditional toxicology data. For previously approved NAMs, minimal additional justification needed. MHRA typically accepts method use in clinical safety assessment and marketing authorization submissions.

Key Documentation Requirements

• Method Description: Detailed SOPs, equipment specs, quality standards, cell sourcing
• Preliminary Validation: Data from 20-50 reference compounds with performance metrics
• Biological Rationale: Literature supporting relevance to human drug response
• Comparative Performance: Comparison with animal studies or human clinical endpoints
• Quality Assurance: Batch consistency, reagent characterization, analytical validation
• Reproducibility: Intra-assay and inter-assay variability data
• Limitations Discussion: Honest assessment of method applicability boundaries

MHRA Contact Information

MHRA vs Other European Regulators

Key Distinguishing Factors:

• Independence: MHRA no longer bound by EMA bureaucratic processes; can implement NAMs policies faster
• Innovation-Friendly: MHRA actively seeking novel method innovations, positioning UK as regulatory hub
• Shorter Timelines: Faster assessment processes than EMA for straightforward applications
• Flexibility: MHRA willing to discuss novel approaches and provide individualized guidance
• Mutual Recognition: Methods approved by EMA recognized by MHRA through bilateral agreements
• Academic Partnerships: Strong UK research community (Imperial College, UCL, Oxford, Cambridge) supporting NAMs validation

Post-Brexit Regulatory Arrangements

Recent Developments (2024-2025)

• MHRA published new guidance on AI/ML-based toxicity prediction acceptability
• Established fast-track pathway for organ-on-chip hepatotoxicity methods
• Formal recognition of OECD Test Guidelines in UK regulatory submissions
• Pilot program for simultaneous UK/EMA submissions using NAMs technologies
• Ongoing development of joint UK-US regulatory recognition agreements on validated NAMs

Best Practices for MHRA Submissions with NAMs

• Early Engagement: Schedule pre-submission advice meeting before major validation investments
• Highlight Innovation: Emphasize scientific innovation and regulatory advancement benefits
• Reference Global Context: Note FDA/EMA acceptance to leverage international precedent
• Comparative Data: Provide head-to-head comparisons with traditional methods
• Published Evidence: Include peer-reviewed publications supporting method validity
• Risk-Based Approach: Align submission with MHRA's risk-based regulatory philosophy

Resources and Further Information

• MHRA Guidance Notes and Procedures - Official regulatory guidance
• MHRA Policy on AI/ML Systems - Guidance on computational methods
• MHRA About Page - Organization and contact information
• Qualification Pathways - International NAMs validation strategies

← Back to Agencies